We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Mutation Identified in Childhood Brain Disorder

By LabMedica International staff writers
Posted on 21 Aug 2018
Pachygyria is characterized by abnormal movement of brain nerve cells, known as neurons, during development of the brain and nervous system and is caused by a breakdown in the fetal neuronal migration process due to genetic or possibly environmental influences.

During normal embryonic growth, immature cells that later develop into specialized nerve cells (neurons) normally migrate to the brain's surface, making several layers of cells. More...
When this process is impaired, the cells do not migrate to their locations, resulting in too few cell layers and absence (agyria) or incomplete development (pachygyria) of gyri.

A team of global genetics experts led by those at Case Western Reserve University Medical School (Cleveland, OH, USA) have discovered a genetic mutation and the faulty development process it triggers, causing a debilitating brain-based disorder in children, known as pachygyria. The scientists used genetic sequencing to study three families affected by the disease, and discovered that children with pachygyria have a mutation in both copies of the alpha-N-catenin gene (CTNNA2), each alteration coming from one parent. The mutation leads to loss of CTNNA2, which the team then showed affected how nerve cells travel from their source of origin in the developing brain to their concluding destination in what eventually becomes the neocortex, a process called neuronal migration.

The investigators found that when CTNNA2 is absent due to genetic mutation, excessive amounts of Actin-Related Proteins (ARP2/3) bind to actin, ultimately disrupting the mechanisms needed for appropriate migrating and branching out of nerve cells. Specifically, resultants ARP2/3 over-activity leads to excessive branching, which impairs neuron growth and stability. The finding raises the possibility of genetic engineering through techniques such as CRISPR-Cas9.

In addition to uncovering a key gene responsible for pachygyria and describing how its mechanisms operate, the scientists discovered a variation of the condition. Typically in cases of pachygyria, either the front or back of the brain displays smooth, non-wrinkled brain surface features. In cases of normal brain development, these areas are convoluted, resembling cauliflower in appearance. In the three families studied, they discovered that both the front and back of the brain were smooth.

The authors concluded that their findings identify CTNNA2 as the first catenin family member with biallelic mutations in humans, causing a new pachygyria syndrome linked to actin regulation, and uncover a key factor involved in ARP2/3 repression in neurons. Ashleigh E. Schaffer, PhD, an assistant professor of genetics and lead author of the study, said, “Our finding that alpha-N-catenin mutations cause pachygyria is an important step in understanding how neuronal development is regulated. The fact that we found this unique feature of back and front smooth brain led us to conclude that a new gene, not previously linked to pachygyria, is responsible. This turned out to be the case,” The study was published on July 16, 2018, in the journal Nature Genetics.

Related Links:
Case Western Reserve University Medical School


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.